Fluidx Medical Developing GPX-Clear Embolic Device With Radiopacity Agent

February 2, 2022—Fluidx Medical Technology, a Salt Lake City, Utah–based company, announced findings of in-vivo research of the company’s GPX-Clear embolic device, which is in development. The device uses Fluidx’s core GPX technology and incorporates an intermediate-term radiopacity agent.

According to the company, the nonartifact-inducing radiopacity agent is trapped within the polymer matrix, which provides visibility of the embolic device during and after embolic delivery. The radiopacity agent then dissipates within 24 hours after delivery, enabling unobstructed visibility of the treated area.

“Our initial in-vivo work with GPX-Clear looks very promising,” commented Ryan O’Hara, MD, in the company’s press release. “It has the advantages of the baseline GPX product around ease of use, minimal preparation, and compatibility with standard microcatheters, with the added benefit of radiopacity that dissipates within the first 24 hours.”

Dr. O’Hara, who is an interventional oncologist at the University of Utah in Salt Lake City, Utah, continued, “There are many instances, particularly in oncology, in which clear visibility of the treated region postembolization is critical and can be obscured by radiopacity agents. This is an exciting future product in the GPX line-up and the first product of its kind.”

According to the company, the GPX technology is intended to stop blood flow for targeted treatment of hypervascular tumors, vessel malformations, internal bleeds, and other cancer-related uses. GPX is a low viscosity, aqueous-based solution in a syringe that solidifies into a durable embolus upon delivery without polymerization or dimethyl-sulfoxide precipitation. GPX is designed for simple preparation and quick material delivery to occlude blood vessels independent of a patient’s coagulation situation.

Fluidx advised that both the GPX-Clear and GPX embolic devices are under development and do not have marketing clearance or approval in any market at this time.

The GPX is only available for investigational use in New Zealand. On January 20, Fluidx reported a challenging case performed with the GPX in a multicenter clinical trial by Martin Krauss, MD, Head of Interventional Radiology at Christchurch Hospital in Christchurch, New Zealand. Dr. Krauss used the device to effectively devascularize a large tumor with multiple feeding vessels as part of a clinical trial.